

Quality Guidelines for Corona Virus Disease 2019 with AGREE II Instrument.

Yao Song¹, Qiurui Liu¹, Jianjun Ren¹, Wenjie Yang¹, Ke Qiu¹, Jianqing Qiu², Wendu Pang¹, Yijun Dong¹, Deying Kang¹, Yu Zhao¹, and Wei Zhang¹

¹Sichuan University West China Hospital

²Sichuan University West China School of Public Health Department of Epidemiology and Health Statistics

April 29, 2020

Abstract

Objective: Numerous clinical practice guidelines (CPGs) for the corona virus disease 2019 (COVID-19) have been developed since its outbreak. To date, however, the methodological quality of these guidelines has not been fully evaluated. Quality evaluation of the guidelines is to facilitate the clinic practitioners in diagnosis and treatment of the COVID-19. **Methods:** The evaluation was conducted by searching seven databases and government organizations websites (December 2019 to March 2020). Four assessors assessed the quality of the CPGs independently with the Appraisal of Guidelines for Research & Evaluation II (AGREE II) instrument. For domain scores (0-100%), >60% were considered of sufficient quality, and >80% of good quality. **Results:** Of 471 retrieved records, 20 guidelines were included. The median score for the domain of scope and purpose was 56.9% (range 40.3–90.3%) and nine guidelines scored >60%, among which three guidelines scored >80%. The median score for the stakeholder involvement domain was 7% (range 0–65.3%) and only two guidelines scored >60%. Nine guidelines scored 0% in this domain. The median score for the rigour of development domain was 0% (range 0–91.7%) and fourteen guidelines scored 0% in this domain. The median score for the clarity of presentation domain was 30.6% (range 13.9–91.7%) and six guidelines scored >60%, among which three guidelines scored >80%. The median score for the applicability domain was 0% (0–57.3%) and eleven guidelines scored 0% in this domain. The median score for the editorial independence domain was 0% (0–100%): four guidelines scored >80%. **Discussions:** Three guidelines were recommendable, and four were recommendable with modification in the stakeholder involvement, the rigour of development, and the applicability domains. Our results could contribute to improve development of future guidelines, and affect the reasonable selection and use of guidelines in clinical practice.

1 Introduction

The corona virus disease 2019(COVID-19), caused by new virus that first reported in Wuhan, China, in mid-December 2019, has so far infected more than 2.4 million people and spread to nearly 211 countries and areas, causing huge losses to public health and property. For standardizing the diagnosis and treatment of COVID-19 infections, the Chinese government, the World Health Organization (WHO) and clinical experts in relevant disciplines around the world have published numerous clinical practice guidelines (CPGs) for COVID-19.

CPGs are regarded as systematically developed statements to assist clinical practitioners in making decisions regarding appropriate health care for specific clinical circumstance¹. However, CPGs drawn up by different groups to respond for same clinic diseases may result in quite difference, even conflicting recommendations, making it difficult for clinic practitioners to choose the superior one. AGREE II (the Appraisal of Guidelines for Research & Evaluation II) is the new (2010) international tool to assess the quality and reporting

of practice guidelines². It can be used to critically appraise the comprehensiveness, rigor, clarity, and applicability, etc., of CPGs.

Furthermore, due to the urgency and damage of COVID-19, plenty of CPGs have been drafted quickly. Therefore, it is necessary and meaningful to evaluate and compare their methodologic quality, which, to date, hasn't been performed. The objective of our present study was to evaluate the quality of currently available COVID-19 guidelines using the AGREE II instrument, so as to assist clinicians in choosing the most appropriate guideline.

2 Methods and Materials

2.1 Information Sources and Eligibility Criteria

The search for the management of COVID-19 CPGs was carried out on March 30, 2020, using documents issued by regional or international groups or government organizations in English and Chinese, through the following search engines using appropriate keywords: Embase; Medline; UpToDate; Cochrane Library; Database for Chinese Technical Periodicals(VIP);China National Knowledge Infrastructure (CNKI); the websites of China national, provincial, local Health and Fitness Commission; the website of WHO. In this study the following keywords were used: 'guideline', 'novel/ new coronavirus', 'COVID-19'. The search was limited to December 2019 and not earlier.

For included CPGs in this research, they must meet the inclusion criteria as follows: (1) the CPGs provide systematically recommendations or strategies in any population with COVID-19 on epidemiology, screening, diagnosis of disease, preventive measures, therapeutic interventions that assists clinical practitioners to make appropriate decisions under specific circumstances; (2) the CPGs was conducted under the concerted effort of public health organizations, professional societies, medical associations, or government agencies at the national, provincial, or local level. Since the role in the assessment of AGREE II of health technology assessments has not been formally evaluated², the exclusion criteria are as follow:(1) guidance documents or handbook that address health care organizational issues, or guidelines were not issued on a regional level; (2)documents that were not guidelines; (3) guidelines that were concerning mainly about traditional Chinese medicine.

2.2 Assessment of Guideline Quality

Four assessors, two were experienced clinicians and the other two were public health fellows with experiences in developing and evaluating guidelines, completed the online overview tutorial and practice exercise recommended by the AGREE collaboration before evaluation².

The assessors independently responded to a total of 23 questions in six domains using the AGREE II instrument: (1) scope and purpose of the guideline, (2) stakeholder involvement, (3) rigour of development, (4) clarity of presentation, (5) applicability, (6) editorial independence^{2, 3}. Each item was rated on a scale of 1 for "strongly disagree" to 7 for "strongly agree"^{2, 3}. On evaluating the 23 items, each appraiser provided an overall assessment of each guideline, and decide if the guideline is recommendable. The decision was based on the personal judgement of assessors and domain scores⁴. In order to reduce discrepancies among four assessors, we referred to a previous method^{4, 5}: if the scores assigned by four appraisers differed by 1 point, the lower was kept; if the scores differed by 2 points, they were averaged; and if the scores differed by [?]3 points, an agreement was reached after discussion.

According to the AGREE II methodology^{2, 4}, domain scores were calculated as follows: (obtained score-minimum possible score)/(maximum possible score-minimum possible)×100%, while the obtained score was defined as the sum of four assessors' scores of each item. Then, as reported in previous researches^{3, 4, 6}, a value >60% was considered as sufficient and a value >80% as good. A median score across all six domains was calculated for each guideline.

3 Results

3.1 Guideline Selection

After screening for relevance in databases, 471 records were initially identified and 43 records were excluded for duplicates. After screening the title and abstract of records, 375 records were excluded because they were about animals, sanitary technical guidance or irrelevant. 53 remaining records were retrieved for full text and 33 records were excluded because they were guidance documents on health work. Finally, 20 CPGs were selected (**Figure 1**). **Table 1** presented the basic information of the included guidelines,

3.2 AGREE II Scores

Four researchers participated in the evaluation of each guidelines and the standardized scores in six domains were shown in **Table 2**.

3.3 Scope and Purpose

The median score for the domain of scope and purpose was 56.9% (range 40.3-90.3%). Guideline 2⁷, 3⁸, 4⁹, 5¹⁰, 14¹¹, 16¹², 18¹³, 19¹⁴, 20¹⁵ scored above 60% for this domain. The other guidelines did not clearly describe their overall objectives, health questions and target populations.

3.4 Stakeholder Involvement

The median score for stakeholder involvement domain was 7% (range 0%-65.3%). Only Guideline 2⁷ and 19¹⁴ scored above 60% in this domain as it clearly defined the target users of the guideline and included individuals from most relevant professional groups. No guidelines considered the views and preferences of the target population.

3.5 Rigour of Development

The median score for rigour of development domain was 0% (range 0-91.7%). Guideline 19¹⁴ had the highest score (91.7%) in this domain because it described systematic method they applied to search for evidence, the strengths and limitations of the body of evidence, the methods for formulating the recommendations, updating procedure, reviewed by experts prior to its publication and considered the health benefits, side effects and risks when developing the guideline. Other guidelines all performed poor in this domain.

3.6 Clarity of Presentation

The median score for clarity of presentation domain was 30.6% (range 13.9-91.7%). Guideline 1¹⁶, 2⁷, 3⁸, 18¹³, 19¹⁴, 20¹⁵ scored above 60% for this domain. Other guidelines did not provide specific, unambiguous and easily identifiable recommendations.

3.7 Applicability

The median score for applicability domain was 0% (range 0-57.3%). Guideline 2⁷ had the highest score (57.3%) in this domain because it described the facilitators and barriers to its application, provided advices and tools on the practice of the recommendations. Guideline 3⁸, as well as the Guideline 2⁷, 6¹⁷, 10¹⁸, 11¹⁹, 18¹³, 19¹⁴, 20¹⁵ also presented monitoring and auditing criteria.

3.8 Editorial independence

The median score for editorial independence domain was 0% (range 0-100%). The scores of the included guidelines in this domain was polarized: Guideline 1¹⁶, 2⁷, 3⁸ and 19¹⁴ scored >80%, and 18¹³ scored 45.8%, while the others all scored 0%.

4 Discussion

No relevant research was found in an extended search on April 23th, this was the first study to systematically evaluate the quality of COVID-19 guidelines with the AGREE II instrument. The overall quality of the 20 guidelines for COVID-19 was highly variable, and significant variability can be seen across domains within guidelines.

Domain scores of scope and purpose in most guidelines were below 60%, indicating that the inclusion and exclusion criteria of target populations and health question remained unclear for early published guidelines.

Stakeholder involvement domains were poorly described, making those guidelines less professional. The involvement of patients in making decision might improve clinical outcomes and increase patients' guideline adherence². Therefore, collecting the views and preferences of target populations is a necessary part of standard guideline, and needs a period of time to carry out. However, considering over 60000 people died, and COVID-19 continues to spread worldwide, no guideline described related information in this item. More attention are ought to paid on the composition of the guideline development team and target population preferences by local and regional guideline developers²⁰.

Systematic reviews are expected to form the basis of high quality of CPGs²¹. The importance had been demonstrated by the guideline manuals published by WHO²². No guideline involved review of outside methodological or health economic experts, which explained all guidelines scored below 60% in the rigor of development domain and suggested a fundamental methodology problem with these CPGs.

Only six guidelines had moderate to high scores in the clarity of the recommendations. This might result from the unclear audience and low scores in stakeholder and rigour of development domain in documents issued by government organizations. CPGs developers should provide a concrete and precise description of different options in different situations, as informed by the body of evidence, and make recommendations easily identifiable to the first-line clinicians audience.

In the applicability domain, most guidelines scored 0%, and did not describe the facilitators and barriers to their application and definite audit criteria. Some CPGs even lacked potential resource and educational tools of applying the recommendations, which might have a great influence on the speed and spread of adoption of guidelines. This finding is inversely proportional to the need of developing guidelines for user-friendliness and clarity suggested in some studies^{4, 23} and should be taken into more consideration when developing new guidelines or updating new versions.

Information on the domain of editorial independence was also neglected in most guidelines. This is particularly important given that influences of the founding body and conflicts of interest are the most common source of bias in guideline development^{23, 24}. Perhaps some guideline developers did not realize the significance of editorial independence disclosures and management. Studies showed that financial conflicts of interest were prevalent among CPGs in a variety of clinical areas²⁴, and some evidence suggested that such financial conflicts of interest might have an influence on guideline recommendations²⁵. Therefore, the guideline developers can't emphasize editorial independence domain enough.

Guideline 2^{7,38} and 19¹⁴ can be recommended to guide clinical practice, while 1¹⁶, 4⁹, 18¹³, 20¹⁵ were recommendable with modification. In view of the urgency of the COVID-19 outbreak, the lower quality and limitations of the early published guidelines are understandable and acceptable. But they are expected to update more evidence-based medical recommendations and modify nonstandard methodology of guidelines to increase their credibility and applicability promptly. And guidelines developers are supposed to focus on not only high speed but also rigorous quality, especially in stakeholder involvement, rigour of development, applicability, and editorial independence domain.

This study had limitation as follows, first, the AGREE II instrument established an appraisal system for methodological quality of guidelines, but the evaluation of guideline recommendations was not stated. Second, the excluded guidelines concerning mainly about traditional Chinese medicine, the next research to work on in our team, might cause this study not to be representative of all CPGs.

In conclusion, the overall quality of CPGs for COVID-19 was uneven. Further research is needed for the appraisal of guideline recommendations. The results of our study could contribute to improve development of future guidelines, and affect the reasonable selection and use of guidelines in clinical practice.

5 Reference:

1. Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice G. In: Field MJ, Lohr KN, eds. *Clinical Practice Guidelines: Directions for a New Program*. National Academies Press (US) Copyright (c) National Academy of Sciences.; 1990.

2. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *CMAJ* . Dec 14 2010;182(18):E839-42.
3. van Diermen DE, Aartman IHA, Baart JA, Hoogstraten J, van der Waal I. Dental management of patients using antithrombotic drugs: critical appraisal of existing guidelines. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* . 2009;107(5):616-624. doi:10.1016/j.tripleo.2009.01.038
4. Chiappini E, Bortone B, Galli L, de Martino M. Guidelines for the symptomatic management of fever in children: systematic review of the literature and quality appraisal with AGREE II. *BMJ Open* . Jul 31 2017;7(7):e015404.
5. Holmer HK, Ogden LA, Burda BU, Norris SL. Quality of clinical practice guidelines for glycemic control in type 2 diabetes mellitus. *PLoS One* . 2013;8(4):e58625.
6. Wong T, Stang AS, Ganshorn H, et al. Cochrane in context: Combined and alternating paracetamol and ibuprofen therapy for febrile children. *Evid Based Child Health* . Sep 2014;9(3):730-2. doi:10.1002/ebch.1979
7. WHO novel coronavirus (2119-nCoV) situation report. World Health Organization. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance>
8. Jin Y-H, Cai L, Cheng Z-S, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). *Military Medical Research* . 2020;7(1):4-4. doi:10.1186/s40779-020-0233-6
9. Diagnosis and Treatment Guideline of New Coronavirus Pneumonia (Trial Version 7). National Health Commission, State Administration of Traditional Chinese Medicine. http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm
10. Diagnosis and treatment of pneumonia caused by new coronavirus infection in Hebei Province. Health Commission of Hebei Province. <http://wsjkw.hebei.gov.cn/index.do?id=396243&templet=content&cid=43>
11. Clinical Nutritional Dietary Guidance for Patients with Pneumonitis Infected by New Coronavirus. Chinese Association of Nutrition, Chinese Medical Association, Chinese Association of Parenteral Nutrition. http://www.gov.cn/fu/02/08/content_5476196.htm
12. Nutritional dietary guidance for the prevention and treatment of pneumonia caused by new coronavirus. Chinese Association of Nutrition, Chinese Medical Association, Chinese Association of Parenteral Nutrition. http://wsjkw.gd.gov.cn/xgzbd/fk/content/post_2899507.html
13. Wang L, Shi Y, Xiao T, et al. Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (First edition). *Annals of translational medicine* . Feb 2020;8(3):47. doi:10.21037/atm.2020.02.20
14. Alhazzani W, Moller MH, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). *Critical care medicine* . Mar 27 2020;doi:10.1097/ccm.0000000000004363
15. Society tAaNZIC. The Australian and New Zealand Intensive Care Society (ANZICS) COVID-19 Guidelines. <https://www.health.nsw.gov.au/Infectious/covid-19/Pages/clinical-guidance-and-resources.aspx>
16. Shen K, Yang Y, Wang T, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement. *World J Pediatr* . Feb 7 2020;doi:10.1007/s12519-020-00343-7
17. Quick Guide to Diagnosis and Treatment of Pneumonia of New Coronavirus Infection (Third Edition). China Medical Herald. <http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html>
18. Expert Consensus on Diagnosis and Treatment of New Pediatric Coronavirus Pneumonia in Guangdong Province. Guangdong Medicine. <https://doi.org/10.13820/j.cnki.gdyx.20200287>

19. Working Group of Novel Coronavirus PUMCH. Diagnosis and clinical management of 2019 novel coronavirus infection: an operational recommendation of Peking Union Medical College Hospital (V2.0). *Zhonghua nei ke za zhi* . 2020;59(3):186-188. doi:10.3760/cma.j.issn.0578-1426.2020.03.003
20. Ye ZK, Liu Y, Cui XL, Liu LH. Critical Appraisal of the Quality of Clinical Practice Guidelines for Stress Ulcer Prophylaxis. *PLoS One* . 2016;11(5):e0155020.
21. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice G. In: Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. *Clinical Practice Guidelines We Can Trust* . National Academies Press (US) Copyright 2011 by the National Academy of Sciences. All rights reserved.; 2011.
22. World Health O. *WHO handbook for guideline development* . 2nd ed ed. World Health Organization; 2014.
23. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. *Jama* . Oct 20 1999;282(15):1458-65. doi:10.1001/jama.282.15.1458
24. Norris SL, Holmer HK, Ogden LA, Burda BU. Conflict of interest in clinical practice guideline development: a systematic review. *PLoS One* . 2011;6(10):e25153. doi:10.1371/journal.pone.0025153
25. Neuman J, Korenstein D, Ross JS, Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. *Bmj* . Oct 11 2011;343:d5621. doi:10.1136/bmj.d5621


Declarations

Funding: This work was supported by The Scientific and Technological Projects for COVID-19 of Sichuan Province [grant number No.2020YFS0007]; COVID-19 Emergency Project of Research Institute,[grant number No. 0082604151010]

Conflict of Interest: The authors declare that they have no conflicts of interest.

Availability of data and material: all data and materials support published claims and comply with field standards.

Figure 1 Flow chart of searching and selecting guidelines



Hosted file

Table.docx available at <https://authorea.com/users/316426/articles/446582-quality-guidelines-for-corona-virus-disease-2019-with-agree-ii-instrument>

